公开资料显示，香港奥星集团是一家科技型制药工程解决方案提供商。作为集团主要成员之一，奥星生 命科学产品与服务事业部业务涵盖无菌药品生产污染控制耗材、设备及服务，环境监控与检测系统，验 证与单机设备，生物上游工艺系统，一次性工艺系统，实验室信息化和生命科学咨询九个板块。奥星生 命科技中期业绩显示，股东应占溢利2499.9万元，同比增加325.37%。 奥星生命科技(06118)尾盘涨幅扩大逾54%，截至发稿，涨48.04%，报1.51港元，成交额847.78万港元。 ...

智通财经APP获悉，奥星生命科技(06118)尾盘涨幅扩大逾54%，截至发稿，涨48.04%，报1.51港元，成 交额847.78万港元。 公开资料显示，香港奥星集团是一家科技型制药工程解决方案提供商。作为集团主要成员之一，奥星生 命科学产品与服务事业部业务涵盖无菌药品生产污染控制耗材、设备及服务，环境监控与检测系统，验 证与单机设备，生物上游工艺系统，一次性工艺系统，实验室信息化和生命科学咨询九个板块。奥星生 命科技中期业绩显示，股东应占溢利2499.9万元，同比增加325.37%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 奧星生命科技有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定 ...

奧星生命科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Current Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications (Note 2) in printed form, please complete, sign the enclosed Request Form and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limi ...

Austar Lifesciences Limited 奧星生命科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：6118） NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 25 September 2025 Austar Lifesciences Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.austar.com.hk and the website of Th ...

中 期 報 告 諮詢、 數字化和 建設 集成工藝與 包裝設備系統 生命科技設備 與耗材 (於開曼群島註冊成立之有限公司) 股份代號 : 6118 (Incorporated in the Cayman Islands with limited liability) Stock Code : 6118 INTERIM REPORT Integrated Process and Packaging Equipment & Systems Consulting, Digitalization and Construction Life Science Equipment and Consumables 奥 Austar Lifesciences Limited 星生命科技有限公司 Interim Report 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 26 | | 未經審核簡明合併財務報表的審閱報告 | 32 | | 中期簡明合併損益表 | 34 | | 中期簡明合併損益及其他綜合收益表 | ...

公司名稱: 奧星生命科技有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Core Viewpoint - Aoxing Life Science Technology (06118.HK) reported a decrease in revenue for the first half of 2025, but significant growth in net profit and order intake, indicating resilience in key projects and operational efficiency [1] Financial Performance - Revenue for the first half of 2025 was RMB 662 million, a decrease of 5.57% year-on-year [1] - Profit attributable to owners increased to RMB 24.999 million, a year-on-year growth of 325.37% [1] - Basic earnings per share were RMB 0.05 [1] Order and Project Performance - Total order amount for the first half of 2025 was approximately RMB 1.0418 billion, an increase of about RMB 135.7 million or 15.0% year-on-year [1] - The integrated process and packaging equipment systems business saw a significant growth of 32.3% [1] - Consulting, digitalization, and construction business segments also experienced a growth of 4.2% [1] Cash Flow and Profitability - Net profit after tax showed a significant increase compared to the same period in 2024 [1] - Operating cash flow increased by over 99% compared to 2024 [1]

Core Viewpoint - Aoxing Life Science Technology (06118) reported a decrease in revenue for the six months ending June 30, 2025, while showing a significant increase in net profit attributable to shareholders [1] Financial Performance - Revenue for the period was 662 million RMB, representing a year-on-year decrease of 5.57% [1] - Net profit attributable to shareholders was 24.999 million RMB, which is a substantial increase of 325.37% compared to the previous year [1] - Basic earnings per share were reported at 0.05 RMB [1]

Group 1 - The company, Aoxing Life Science Technology (06118), reported a revenue of 662 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 5.57% [1] - The net profit attributable to shareholders was 24.999 million RMB, showing a significant year-on-year increase of 325.37% [1] - The basic earnings per share were reported at 0.05 RMB [1]